Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Prevention of Pre-eclampsia (PREMET)
NCT04855513Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of metformin in preeclampsia (2 arms), sponsored by Hamad Medical Corporation. Primary endpoints: Incidence of Pre-eclampsia (PET) and PIGF/sFlt-1 as a prognostic marker in PET. Status: unknown.
02
Drugs
metformin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT04855513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855513.